The relationship of anticardiolipin antibodies (ACA), markers of the antiphospholipid syndrome, with vascular complications of diabetes mellitus is polemic. This cross-sectional study assessed the frequency of IgG, IgM, and IgA ACA in type 2 diabetics with and without history of vascular events for the last 5 years, and in healthy controls. ACA were detected by enzyme immunoassay. A total of 73 type 2 diabetics (33 with history of vascular events) and 54 healthy controls were tested. Most diabetics were female (p = 0.003), and older than controls (p < 0.001). Mean duration of disease was 10 years. The prevalence of a positive ACA test was 7.4% in controls and 9.5% in diabetics (p = 0.910). Comparison of healthy controls and diabetics with and without history of macrovasculopathy, after adjusting for gender and age, showed no significant differences as to the presence of ACA (p > 0.09). ACA positivity rates were also similar when diabetics with and without history of vasculopathy were compared (p > 0.47). After adjusting for gender, age, hypertension, and smoking status, a weak but statistically insignificant association between IgM ACA and diabetics with vasculopathy was found (adjusted OR 2.7; 95% CI 0.2 -34.2; p = 0.441). Overall, levels of IgG (r = 0.25; p = 0.005) and IgM (r = 0.23; p = 0.010) ACA were associated with increasing age. In short, the frequency of a positive ACA test in type 2 diabetics (with or without previous macrovasculopathy) was not significant as compared to healthy controls. There was no association of ACA with vascular events in patients with type 2 diabetes.
Anticardiolipin antibodies (ACA), as well as the lupus anticoagulant and antibodies to beta2-glycoprotein (beta2-gpI), are classical markers of the antiphospholipid syndrome (APS) [1] . The relationship of ACA with vascular complications of diabetes is rather unclear.
This cross-sectional study assessed the frequency of IgG, IgM, and IgA ACA in type 2 diabetics [2] with and without history of macrovascular events (myocardial and/or cerebral infarction) for the last 5 years, and in healthy controls. ACA were detected by enzyme immunoassay (ORGENTEC Diagnostika GmbH-Anti-Cardiolipin). Titers were considered as positive when above 10 GPL for IgG ACA, 10 MPL for IgM ACA, and 7 units for IgA ACA [3] . The study was approved by the local ethics committee.
Chi-square analysis were used for comparison of categorical variables, and the Student's t test was used for comparison of continuous variables. A level of 5% (p < 0.05) was considered significant. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated for univariate analysis. Logistic regression with 95% CI was performed to adjust the effects of gender, age, hypertension [4] , and current smoking [5] in the OR. When needed, Agresti correction was employed to obtain nonadjusted OR. To co-relate quantitative variables, the Pearson coefficient was utilized. All analyses used procedures of the SPSS for Windows, version 11.5, Chicago, IL.
A total of 73 type 2 diabetics (33 with history of vascular events) and 54 healthy controls were tested. Most diabetics were female (p = 0.003), and older than controls (p < 0.001). Mean duration of disease was 10 years. The prevalence of a positive ACA test (any isotype) was 7.4% in controls (5.6% IgA ACA) and 9.5% in diabetics (p = 0.910).
Comparison of healthy controls and diabetics with or without history of macrovasculopathy, after adjusting for gender and age, showed no significant differences in ACA positivity (p > 0.09). ACA frequency rates were * Corresponding author.
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also similar when diabetics with and without recent history of vascular events were compared (p > 0.47).
Females significantly predominated in diabetics without vasculopathy as compared to diabetics with previous vascular events. After adjusting for gender, age, hypertension, and smoking status, a weak but statistically insignificant association of IgM ACA and diabetics with vasculopathy was found. These data can be seen in Table 1 .
Overall, levels of IgG (r = 0.25; p = 0.005) and IgM (r = 0.23; p = 0.010) ACA related to increasing age.
Type 2 diabetes comprise an independent risk factor for atherosclerotic disease. The etiopathogenesis of the micro and macrovascular complications of type 2 diabetes are not fully understood. Macrovascular obstructions affecting the coronary and cerebral arteries are the main cause of mortality in diabetics [6, 7] . ACA and endothelial dysfuncion might be synergistic for vasculopathy in insulin-dependent diabetes [8] .
For the last decade, we have documented a defined association of IgA anti-beta2-gpI antibodies with cerebral ischemia [9] , coronary disease [10] , carotid disease [11] , and peripheral artery disease [12] . Only in one of these studies [12] , IgA ACA associated with the outcome. More recently, we demonstrated an association of the IgA anti-beta2-gpI antibody with metabolic syndrome; once more, the ACA prevalence was low [13] . We therefore infer that ACA do not relate to acute or chronic atherosclerotic disease, nor to metabolic syndrome. The relationship of ACA with type 2 diabetes and diabetic vasculopathy had not been so far evaluated in our research center.
In the current study, ACA positivity was similar in controls and type 2 diabetics (7.4% and 9.5%, respectively). There was no statistical difference as to the ACA prevalence in the two groups. The frequency of IgA ACA in our healthy controls (5.6%) was quite impressive, and this is an issue to be further addressed. Differently from our data, Hendra et al reported a significant frequency of IgG ACA in diabetics with or without coronary disease [14] . Gargiulo et al. described elevated levels of IgA anti-phosphatidylethanolamine, but not ACA, in type 1 or 2 diabetics as compared to controls [15] . Similarly to our findings, the prevalence of ACA in non-complicated diabetes was irrelevant in another previous study [16] .
When our two groups of diabetics were compared, a weak association of IgM ACA with complicated diabetes was suggested by the adjusted OR, but this finding was statistically insignificant. Of interest, the frequency of ACA in type 1 or 2 diabetics with macroangiopathy and nephropathy was higher as compared to patients with non-complicated or well-controlled disease [16] . Another group of authors reported, in 1989, an increased positivity for IgG and IgA ACA in type 2 diabetics with macrovascular disease [17] . As seen, data concerning prevalence of ACA in diabetes are incongruent.
We herein documented a significant correlation of IgG and IgM ACA with increasing age. This is in accordance with the study by Fields et al., whereby IgG and IgM ACA were detected in 12% of the healthy elderly and in 2% of younger adults [18] . As opposed to that, ACA positivity in the elderly was reported to be insignificant and similar to younger populations [19] .
In general terms, our results pointed to a insignificant positivity for ACA in type 2 diabetes. A low prevalence of ACA was seen in both complicated or non-complicated diabetic populations. These data, although limited by the small sample, do not favour a pathogenetic role for ACA in type 2 diabetes and diabetic macrovasculopathy. Our findings are corroborated by those reported by Tarkun et al., which desvinculated ACA from vascular complications of type 2 diabetes [20] .
In summary, the frequency of a positive ACA test in type 2 diabetes (complicated or not by macrovasculo- 
